MetaHealth Ventures Portfolio Company Huamai Tech Hosts 'Brilliance Shines, Pulsing Future' Symposium at the 14th Central Plains Endovascular Conference (CPEC 2024)

Jul 30, 2024 17:20 CST Updated 17:20

Percutek Therapeutics

Developer of Minimally Invasive Cardiovascular Treatment Devices

Click on the "blue words" above to follow more exciting content.

Recently,The 14th Central Plains Vascular Forum (CPEC 2024)The 2024 Annual Meeting of the Vascular Surgery Management Branch of the Henan Provincial Hospital Association, the 2024 Central Plains Vascular Forum Nursing Forum, the Annual Meeting of the Central Plains Vascular Debulking Alliance (CPED), and the Annual Meeting of the Henan Venous Alliance (HNPU) successfully concluded in Zhengzhou, Henan. During this conference,Beijing Percutek Therapeutics Medical Equipment Co., Ltd. (hereinafter referred to as "Percutek Therapeutics")Honored to join hands with renowned experts and young experts in China, focusing on the field of aortic and peripheral interventional treatment, we have meticulously crafted high-quality and high-level academic lectures to showcase the latest technologies and treatment concepts.

YuanSheng Ventures participated in the Series C financing of Percutek Therapeutics in October 2016.

This session has specially invited Professor Weiwei Fu from Zhongshan Hospital Affiliated to Fudan University and Professor Shuiting Zhai from Henan Provincial People's Hospital to serve as the conference chairs. Professor Zhen Li from the First Affiliated Hospital of Zhengzhou University, Professor Jian Zuo from Xijing Hospital of Air Force Medical University, and Professor Wendong Cao from Shanxi Bethune Hospital will serve as the meeting moderators. Professor Xiao Tang from Zhongshan Hospital Affiliated to Fudan University, Professor Liao Yang from Beijing Anzhen Hospital affiliated to Capital Medical University, Professor Qiang Liu from the First Affiliated Hospital of Nanchang University, Professor Chuan Liang from Zhongnan Hospital of Wuhan University, and Professor Haihan Kang from the Second Affiliated Hospital of Zhengzhou University will serve as sharing guests.

"The Art of Breaking Bamboo - Strategies and Practices for Reconstructing Branches Above the Aortic Arch"

Zhongshan Hospital Affiliated to Fudan UniversityProfessor Kang Xiao

First, Professor Tang Xiao analyzed the current status of endovascular treatment technology for aortic diseases. He pointed out that the current in-situ fenestration technology can fully match the patient's anatomical structure. The experience of Futhrough in-situ fenestration used by Fudan Zhongshan shows that the three-year patency rate is over 90%, but it requires the support of new instruments. The existing commercial main stent graft materials have irregular orifice shapes after being expanded during in-situ fenestration, or are not easy to puncture, or have strong rebound force, which can easily lead to occlusion and high risk of endoleaks.Percutek TherapeuticsWith meticulous dedication, clinical problems are effectively solved. Through innovative weaving technology, a main stent material that fits perfectly with in-situ fenestration has been developed. The material is divided into a conventional area and a new technology area. After expansion with a 9mm balloon at 7ATM, the fenestration diameter exceeds 5.5mm, with no fragmentation or detachment at the edges. Currently, it has shown excellent performance in over twenty real-world cases of in-situ fenestration for the left subclavian artery, and its safety and efficacy have been preliminarily verified. Professor Tang Xiao further shared his application experiences across multiple lesion cases, including aortic arch ulcers and aortic arch aneurysms.

"Breaking Bamboo Victory - Innovative Application of Domestically Produced Thoracic Devices"Main Stent TEVARSurgical Combined In-situ Reconstruction of LCCA+LSA

Beijing Anzhen Hospital, Capital Medical UniversityProfessor Yang Liao

Professor Yang Liao mentioned that the current endovascular treatment methods for supra-aortic branch reconstruction mainly include bypass surgery, chimney technique, branched stents, in vitro pre-fenestration, and in-situ fenestration. Traditional in-situ fenestration of aortic covered stents has higher requirements for interventional devices, necessitating special equipment such as in-situ fenestration needles, lasers, and biopsy needles. However, when in-situ needle fenestration, laser fenestration, or in vitro pre-fenestration of supra-aortic branches is challenging, guidewire fenestration becomes a viable option.Percutek TherapeuticsMastering the relationship between weaving methods and membrane permeability and penetration, the innovative polyester weaving process optimizes the membrane material. When performing supra-arch branch fenestration through a guidewire, it can be easily penetrated and expanded, with good stent morphology post-implantation, tight window edge structure, and no fractures or detachment. Professor Yang Liao further shared his experience using a thoracic aortic aneurysm LCCA+LSA double fenestration case. He performed endovascular aortic repair with in-situ branch reconstruction using a 0.018" CTO guidewire with a soft tip for membrane penetration. The procedure has a shorter learning curve and reduces the requirements for selecting endovascular instruments.

"Strategies for Managing Aortic Diseases Involving the Arch"

The First Affiliated Hospital of Nanchang UniversityProfessor Liu Qiang

Professor Liu Qiang mentioned that the future treatment of vascular diseases will surely be an individualized treatment pattern dominated by endovascular techniques, supplemented by hybrid surgery, and guaranteed by open surgery. In usePercutek TherapeuticsThe new process optimization of the covered stent allows for easy operation when performing in-situ reconstruction of the LSA through a guidewire, reducing the selection requirements for endovascular devices. Postoperative fenestrated stent morphology is regular with no leakage around, showing satisfactory results. Additionally, it demonstrates potential in the application of techniques such as the use of puncture kits or ex-vivo fenestration.Percutek TherapeuticsWhen using the Percutek Therapeutics® thoracic aortic stent graft for arch reconstruction, it is also appreciated for its precise positioning, secure anchoring, excellent sealing performance, appropriate radial support, superior flexibility and conformability, and ease of retrieval. For the treatment of arch-related dissections, intramural hematomas, penetrating ulcers, aneurysms, and other conditions, it can be selected.Percutek TherapeuticsThoracic aortic stent graft was used for treatment.

"Breakthrough Repair - Case Sharing of Residual End Management After Open Surgery for Thoracic Aortic Dissection"

Zhongnan Hospital of Wuhan UniversityProfessor Liangchuan

Professor Liangchuan mentioned that despite a decade of exploration, the in-situ fenestration technique still faces three major challenges: ensuring its safety and efficacy, the risk of occlusion caused by the recoil of the membrane material squeezing the branch stent, and the risk of endoleaks due to the irregular circular shape of the fenestration window. Meanwhile, domestically produced...Percutek TherapeuticsAble to deeply cultivate technology, its new process optimization of woven coated materials has achieved a technological breakthrough in arch reconstruction. Subsequently, Liang Chuan shared a case of right coronary artery repair + aortic valve plasty + ascending aorta replacement + aortic arch plasty + thoracic endovascular aortic repair (TEVAR) stent graft implantation performed at another hospital. Post-ascending aorta replacement, there was stenosis at the suture site; after aortic arch plasty, the originally placed stent graft’s metal wire was visible. The original stent graft already had a fenestration at the root of the left subclavian artery, which has now formed a secondary rupture. The left subclavian artery originates from the anterior lateral wall of the aortic arch, forming an acute angle with the aortic arch. This case is complex and used...Percutek TherapeuticsThe new process optimizes the covered stent for guidewire in-situ fenestration reconstruction, with relatively simple operation, precise stent release, firm anchoring, no membrane leakage, and excellent immediate and short-term effects.

"Rapid Thrombus Clearance - Strategies and Practices for Acute and Subacute Thrombus Management"

The Second Affiliated Hospital of Zhengzhou UniversityProfessor Kang Haihan

Professor Kang Haihan mentioned that for the treatment of deep vein thrombosis (DVT) in the lower limbs, percutaneous mechanical thrombectomy (PMT) or manual thrombectomy are currently the mainstream interventional surgical treatment methods, and contact catheter-directed thrombolysis (CDT) can be used when necessary. In addition, Professor Kang Haihan recommended addressing iliac vein stenosis in the first stage, which can reduce the risk of DVT recurrence caused by iliac vein stenosis and also lower the cost of secondary treatment for patients. Professor Kang Haihan specifically mentioned,Percutek TherapeuticsThrombolytic catheter, featuring an adjustable injection pump, 360° uniform and powerful spray, and a complete range of models. Its effective range covers the iliac vein and inferior vena cava, efficiently cooperating with mechanical or manual thrombus aspiration to treat DVT.

About Percutek Therapeutics

Beijing Percutek Therapeutics Medical Equipment Co., Ltd. is a high-tech enterprise focused on the research, development, and application of innovative products and therapies in the field of vascular disease treatment. Its main business includes the research, development, production, and sales of medical device products in the fields of aortic, peripheral and coronary, neuro-intervention, and access. The company adheres to self-research and development guided by addressing the clinical needs of patients with vascular diseases in China. Through the accumulation and application of innovative technologies, it continuously overcomes clinical challenges in the field of vascular disease treatment, providing doctors and patients with high-quality products and solutions for vascular disease treatment. The company is committed to becoming a platform-based medical device company rooted in China with world-class technology and competitiveness in the field of vascular disease treatment, benefiting patients with vascular diseases worldwide.

END

About Yuanbio Venture Capital

Yuansheng VenturesIt is an investment institution focused on the early and growth-stage healthcare sector, based in Suzhou BioBAY with a global reach. To date, it has completed investments in over 180 outstanding enterprises in the life sciences and healthcare field, covering four major areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as healthcare services, achieving substantial investment returns. Among these, 19 companies have gone public on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanSheng Venture Capital has been repeatedly ranked among the Top 10 venture capital funds in China's healthcare sector and recognized as one of the most active healthcare investment institutions in China. With a team of seasoned professional investors and a world-class scientific advisory board, YuanSheng Venture Capital boasts extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry. Leveraging its expertise, focus, and abundant industry resources, we are committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.